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DNA DAMAGE SIGNALING IN RENAL CANCER CELLS 
ROBERT W. SCHULZE III 
 
ABSTRACT 
 DNA damage elicits a complex and detailed repair response involving multiple 
pathways. Defects in these pathways can result in a myriad of problems including 
tumorigenesis and cancer. By delving into the nuances controlling the DNA damage 
response in renal cancer cells, a greater understanding of relationships between related 
factors can be created. Historically, much of our understanding of general diseases comes 
from specific areas of damage. The findings and experimentation involving von Hippel 
Lindau (VHL) disease sheds light on the core factors of renal cancer. VHL disease 
patients are shown to be lacking a protein, pVHL, which is core in one of the tumor 
suppressing pathway. This study works towards investigating the effects of the missing 
protein in cells and the effects on related tumor suppressing proteins. In testing and 
recording the response of the pVHL deficient 786-O renal cancer cell line, which is 
relevant to VHL disease and sporadic renal cancer, predictions about the strength of the 
DNA damage response can be made. Ultimately the data collected were inconclusive 
because the positive control did not work.  Moreover, the data were also variable, which 
made analysis troublesome. Different durations of exposure to a DNA damaging agent 
resulted in erratic responses. Further probing into tumor suppression pathways holds 
promise for the future of cancer treatment. 
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INTRODUCTION 
 
Origins of cancer 
 Cancer has plagued mankind continually with descriptions of tumors first coming 
from the Edwin Smith Surgical Papyrus dating back before 2000 B.C. (Lakhtakia 2014). 
Through time cancer has been defined differently but often with enough descriptions to 
ensure its historical knowledge. After the earliest recordings from ancient Egypt, the 
humoral theory believed to be from Hippocrates in the 400 B.C. described tumors as an 
imbalance of black bile (Sudhakar 2009). While the humoral theory is ridiculed by many 
today, evidence suggests we have been wrong more often than right. As recent as 100 
years ago cancer was believed to originate from trauma, and it’s hard to fault scientists 
without knowledge of DNA (Sudhakar 2009). While we have discovered a great deal 
leading up to today’s understanding, the history of cancer and advancement of medicine 
stretches back as far as mankind. With the amalgamation of research through the past 60 
years the developments in cancer understanding and treatments have been refined 
tremendously. 
 Cancer is a general term for diseases incurred by faulty cell growth, typically due 
to DNA damage or a nonfunctioning mechanism in a protein regulation pathway. While 
our knowledge about cancer is increasing, so are the rates of incidence in some forms of 
cancer, seemingly related to smoking, obesity, and hypertension (Turajlic, Larkin, and 
Swanton 2015). The ever increasing need for improvements in cancer treatment, therapy, 
and management produce a looming urgency. 
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 We know that some cancers have the ability to metastasize, allowing them to 
move between different regions of the body and invade other organ systems. The ability 
to metastasize confers the lethality associated with many cancers (Fidler and Kripke 
2015). These cancers are most often seen in areas of the body either with high blood flow 
or direct access to other regions of the body, such as the lungs or kidneys. Cancer can be 
incredibly evasive and treatments often damage collateral tissues. This is because 
cancerous cells are nearly identical to healthy cells when compared to bacteria or foreign 
substances. Cancerous cells can grow and spread so rapidly due to neutralizing or losing 
some of the cellular replication controls normally exhibited. Many current methods for 
targeting cancerous cell lines in therapy use treatments aimed at take advantage of this 
unique property. The unchecked reproduction of cancerous cells can occur for a 
multitude of reasons. One of the most prevalent types results from a failure to stop at 
checkpoints in the mitotic pathway, others transpire due to an increased expression of 
angiogenic factors promoting blood vessel formation and growth. Special forms of cancer 
can result in global changes within the body depending on the origin of the cancer. A 
prime example of this is the formation of hormone releasing tumors in endocrine organs 
such as in the pituitary or thyroid glands (Kunz 2015).  
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DNA damage Response 
Eukaryotes have developed highly conserved mechanisms of DNA damage repair 
necessary for survival and reproduction (Harper and Elledge 2007). The DNA damage 
response pathway functioning rapidly and precisely is critical for the survival of cells. 
Organized DNA repair is needed because each cell encounters thousands to tens of 
thousands of DNA lesions and damage every 24 hours (Jackson and Bartek 2009). A 
wide variety of sources can incur DNA damage, including numerous unavoidable 
instances such as ultraviolet light radiating from the sun (Jackson and Bartek 2009). 
Other lesser known carcinogens like the chemical neocarzinostatin from Streptomyces 
macromyceticus (NCS) are used in numerous experiments for their potency as a DNA 
damaging agent. Some more common carcinogens that are encountered include cigarettes 
and overcooked meats (Doll and Peto 1981) (Wogan et al. 2004). 
 DNA damage frequently requires different mechanisms of repair based on the 
category of mutation. Cells responds in different fashions depending on the type of DNA 
damage (Ciccia and Elledge 2010). A single base replacement only requires mismatch 
repair in comparison to a pyrimidine dimer producing the more complex nucleotide 
excision repair. While mismatch repair removes an incorrect nitrogenous base from DNA 
and replaces it with the correct match, nucleotide excision repair cuts out the DNA and 
phosphodiester backbone in the neighboring areas to replace the region entirely.  Double 
stranded breaks are considered the most involved and precarious type of DNA damage 
(Ciccia and Elledge 2010). Double stranded breaks are repaired via mechanisms 
including homologous recombination, non-homologous end-joining, single-strand 
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annealing, and microhomology-mediated end joining (Hartlerode and Scully 2009). More 
complex still is the co-operation or competition of some of these repair mechanisms. 
 
 
Origins of VHL Protein Identification 
 von Hippel-Lindau (VHL) disease is an autosomal dominant illness first described 
in 1911 by Eugen von Hippel and later connected to related symptoms by Arvid Lindau 
(Ben-Skowronek and Kozaczuk 2015). As tools improved and theories surrounding DNA 
progressed the genomic origin of VHL was brought into focus. By 1988 the 
understanding that damage to chromosome 3p25 resulted in VHL disease was discovered 
via positional cloning techniques and the comparison of multiple unrelated VHL patients 
(Seizinger et al. 1988). This was further elucidated with the development of pulsed field 
gel electrophoresis confirming the VHL gene location and generating detailed genomic 
maps of the region (Yao et al. 1993). 
VHL disease appears in roughly 1/36,000 live births and requires a mutation of 
the alleles coding for VHL (Lefebvre and Foulkes 2013). People born with heterozygous 
germline mutations for VHL disease typically start with one VHL gene deactivated. This 
develops into a problem later as the second VHL allele becomes inactivated in a cell, 
leading to the inability to produce a wild-type VHL protein (pVHL) (Knudson 1971). In 
normal cells, having the second, normal allele for VHL allows for the random damage of 
a single allele without repercussion. This leads to the next form containing random 
mutation of both VHL genes. In a review by Gossage, Eisen, and Maher (2015) the 98% 
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occurrence of loss of both VHL genes in clear cell renal cell carcinoma (CCRCC) is 
highly indicative of a link between the two. The effects of damage to the VHL gene are 
devastating and difficult to manage. 
VHL disease greatly increases the likelihood of renal tumors, cerebellar 
hemangioblastomas, and other visceral tumors (Ben-Skowronek and Kozaczuk 2015). 
Damage resulting in inactivation of VHL leads to absence of wild-type pVHL protein and 
results in increased presentation of highly vascular solid clear cell renal cell carcinomas 
(Ben-Skowronek and Kozaczuk 2015). The early identification of VHL disease is 
important in the monitoring and treatment of renal tumors and other central nervous 
system (CNS) effects for patients (Ben-Skowronek and Kozaczuk 2015). 
The damage and loss of a functional VHL gene is the cause of 90% of clear cell 
renal carcinomas (Gnarra et al. 1994). The inactivation of VHL is the most frequent 
genetic occurrence in kidney cancer in humans indicating the core importance of it in 
regulating tumor growth (Kaelin and Maher 1998). Other tumorigenic effects of VHL 
disease reside in the growth of retinal angiomas and  central nervous system 
hemangioblastomas (Wang et al. 2014) . 
 Currently,  therapy for VHL disease focuses on managing the tumor and cyst 
growth. Pharmacological approaches using drugs including multi-targeted receptor 
tyrosine kinase inhibitors sunitinib, sorafenib, pazopanib, and axitinib do intercept some 
of the key angiogenic pathways upregulated in VHL disease (Kim and Zschiedrich 2018). 
Renal tumor monitoring and removal is shown to be a difficult issue in VHL patients.  
Unfortunately the repeated surgical removal or ablation of renal tumors in VHL disease 
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lead  to loss of kidney mass, necessitating dialysis or  kidney transplant (Jilg et al. 2012). 
Another important note is that the growth rate of tumors is tied to their rate of metastasis, 
with the fastest growing tumors compromising the most threat (Jilg et al. 2012).  
 
VHL Pathway 
The presence of von Hippel-Lindau protein is one of the major factors controlling 
cell apoptosis and operates as a renal tumor suppressor (Iliopoulos et al. 1995). pVHL 
slows cell growth and inhibits apoptosis (Zhou et al. 2005; Vortmeyer and Alomari 
2015). One well-defined function of pVHL is the degradation of hypoxia-inducible 
factors (HIF) (Maxwell et al. 1999). HIF is heavily upregulated in the event of  cell 
hypoxia and causes the activation of genes encoding erythropoietin and vascular 
endothelial growth factor (VEGF) (Kallio et al. 1997). The constitutively active effect of 
these growth factors leads to highly vascularized neoplasms (Nyhan, O’Sullivan, and 
McKenna 2008).  With normal pVHL, HIF levels are kept in low; however, HIF levels  
are constitutively high, independent of present oxygen levels in the absence of pVHL 
(Tanimoto et al. 2000). pVHL functions in a complex to work as a ubiquitin ligase for a 
number of proteins, including HIF, for proteasomal degradation. . The absence of pVHL 
or of any of the components in the complex leads to high expression of HIF which results 
in overexpression of angiogenic factors in renal cancers (Cohen and McGovern 2005) 
(Mandriota et al. 2002).  
The aforementioned complex mediates an interesting relationship between HIF 
and Elongin  C and B. The successful binding of Elongin C, B and Cul-2 to VHL 
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promotes and assists in the ubiquitination of HIF as can be seen in Figure 1. (Lonergan et 
al. 1998; Nyhan, O’Sullivan, and McKenna 2008). This effect can be indirectly 
distinguished with damage to the gene encoding for Elongin C, ELOC (Hakimi et al. 
2015). With malformed or absent Elongin C, the binding to VHL and creation of a 
complex is impaired (Sato et al. 2013). The absence of the pVHL/Elongin/Cul-2 complex 
ubiquitination diminishes the ubiquination of HIF proteins resulting in consequences 
identical to VHL deficient cells. In effect, the well understood repercussions of VHL 
absence can be partially replicated by interfering with proteins required for the formation 
of the pVHL complex (Schoenfeld, Davidowitz, and Burk 2000). With removal of each 
of the pieces of the pVHL complex it becomes evident that all are simultaneously 
required for regulation of HIF (Schoenfeld, Davidowitz, and Burk 2000).  
Some unique properties exist around ELOC mutations. In the event of gene 
damaged it nearly always occurs specifically at the problem area tyrosine residue 79. 
Additionally, the gene showed a novel phenomenon. Any damage to TCEB1 was 
consistently reflected in the companion allele upon inspection (Hakimi et al. 2015). 
A regulation pathway is indirectly expressed by VHL through the interactions 
with Elongin proteins in the formation of the pVHL ubiquitin ligase complex. pVHL is 
able to prevent formation of Elongin (SIII) transcription elongation complex, a 
heterotrimer consisting of subunits Elongin A, B, and C, although the importance of this 
mechanism as yet unclear.  VHL tightly binds Elongin C at its 35 residue domain 
resulting in the inhibition of the Elongin (SIII) complex (Stebbins, Kaelin, and Pavletich 
1999). In addition, the creation of the Elongin/VHL complex is resistant to proteasomal 
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degradation, ensuring stabilized concentrations of the components (Schoenfeld, 
Davidowitz, and Burk 2000).  
Suppression of the vascular endothelial growth factor (VEGF) is another method 
of tumor suppression exerted by VHL (Siemeister et al. 1996). Repression of VEGF 
promoter was demonstrated in pVHL positive cells. pVHL binds and inhibits Sp1 
transcription factor, which is an important part of this mechanism (Mukhopadhyay et al. 
1997). Moreover, suppression of HIF by pVHL also results in further suppression of 
VEGF gene expression. 
 
 
Morphogenesis 
Interestingly, an additional effect of pVHL is noticeable related to the 
invasiveness of tumorigenic cells. In an experiment done by Koochekpour et al. (1999)  
the relationship between VHL and the tissue inhibitor of metalloproteinase 2 (TIMP-2) 
was dissected. The 786-O renal cell line lacking VHL was compared to wild-type cells in 
the study of TIMP2. In the presence of pVHL, TIMP-2 is maintained at normal levels as 
compared to the reduced levels in pVHL deficient cells. The drop of TIMP-2 associated 
with the absence of VHL results in a more invasiveness in the event of tumorigenesis as 
measured by the increase in branching morphogenesis displayed in vitro (Koochekpour et 
al. 1999). Furthermore, they tested the response of 786-O cells to hepatocyte growth 
factor (HGF), a modulator of mitotic replication functioning through the met kinase 
pathway. HGF is normally expressed in human kidneys making its relationship to the 
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most common form of kidney cancer (VHL negative) pertinent. HGF was shown to cause 
branching morphogenesis in CCRCC cells with the absence of VHL, additionally 
reintroduction of VHL inhibited the invasiveness in the cell line (Koochekpour et al. 
1999). 
Another related piece to the branching morphogenesis factor was found in other 
research revealing the chaotic cell growth in the absence of VHL (Davidowitz, 
Schoenfeld, and Burk 2001). VHL is important to renal cell differentiation and is 
involved in cell to cell and cell to extracellular-matrix organization (Davidowitz, 
Schoenfeld, and Burk 2001). Another important function of pVHL is the stabilization of a 
protein known as Jade-1(Zhou et al. 2002).  
 
Jade-1 
pVHL bind and stabilizes Jade-1, a pro-apoptotic tumor suppressor protein highly 
expressed in the kidney. Chromosome 4q is the originating location for Jade-1 (Zhou et 
al. 2002). pVHL binds to Jade-1 and prevents its breakdown via the proteasome pathway 
(Zhou et al. 2005). The absence of pVHL therefore reduces Jade-1protein levels. This 
was shown with proteasome inhibitors resulting in a greater increase in Jade-1in pVHL 
deficient cells as compared to pVHL transfected cells.  Jade-1 expression is high in renal 
non-cancerous cells and very low levels in cancerous cell lines (Xiao-Fen et al. 2016). 
Working in tandem with the HBO1 histone H4 acetyltransferase, Jade-1 functions 
as a transcription regulator (reviewed in Panchenko 2016). When overexpressed, Jade-1 
stabilizes of HBO1, resulting in a cooperative increase in histone H4 acetylation. The 
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acetylation of histone H4 is associated with transcription and chromosome assembly 
(Chahal, Matthews, and Bradbury 1980). Further it was shown that deletion of the plant 
homology domain (PHD) zinc fingers from Jade-1completely abrogated the histone 
acetylation (Foy et al. 2008), 
Another indirect mechanism of Jade-1 is the downregulation of B-cell lymphoma 
proteins. This pathway explains some of Jade-1’s control of apoptotic effects (Zhou et al. 
2005). Interestingly, this may be offset by anti-apoptotic effects of pVHL by upregulating 
B-cell lymphoma proteins, such as Bcl2. This leads to a dynamic between pVHL and 
Jade-1 competing for control of the B-cell lymphoma exerting control of renal cell 
apoptosis (Zhou et al. 2005).  Additional research into Jade1 and VHL will be useful to 
further our understanding of cellular repair and renal tumorigenic pathways. 
 
lncRNA-Jade 
A relationship between Jade-1 histone acetylation and the DNA damage response 
appears to be connected through lncRNA-JADE. lncRNA-JADE is a transcriptional 
activator of Jade-1. Wan et al., (2013) showed that decreasing lncRNA-JADE resulted in 
lowered Jade-1 levels. Conversely, overexpressing lncRNA-Jade increased Jade-1 mRNA 
levels. When lncRNA-JADE was found to be overexpressed in breast cancer cells 
compared to normal tissue, Wan et al. ( 2013) further tested the response of lncRNA-
JADE to DNA damage. Using NCS to elicit DNA damage increases lncRNA-Jade in 
MCF7 breast cancer cells, suggesting its involvement in the DNA damage response.  
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While the preservation of lncRNAs across species is not high in general, lncRNA-
JADE is an exception as part of the highly conserved DNA damage response pathway 
(Johnsson et al. 2014; Wan et al. 2013). The preservation of important tumor suppressor 
lncRNA across most eukaryotes would be unsurprising. The dysregulation of lncRNA-
JADE increases risk of tumorigenesis (Wan et al. 2013). The ataxia-telangiectasia 
mutated (ATM) kinase pathway is one of the major responses to double stranded DNA 
damage. ATM in tandem with its regulating MRN protein complex is able to detect 
double stranded DNA breaks (Matsuoka et al. 2007). Wan et al. (2013) proves the 
relationship of the ATM pathway to lncRNA-Jade using a modified method from their 
earlier experiment. When a DNA damaging agent is used in addition to an ATM inhibitor 
in MCF7 breast cancer cells, the induction of lncRNA-JADE is prevented showing the 
reliance on ATM for lncRNA-JADE. A similar experiment was done on the tumor 
suppressing p53 pathway which is activated by ATM to confirm the independence of 
lncRNA-JADE from p53. While both the ATM pathway and p53 are known pathways in 
tumor suppression, only the ATM pathway is related to the control of lncRNA-JADE. 
The main focus of the Wan et al. (2013) research was the link between lncRNA-Jade 
upregulating Jade-1leading to the acetylation of histone H4. The management of histone 
4 acetylation is important in controlling chromatin remodeling (Annunziato and Seale 
1983). The promotion of Jade-1from lncRNA-JADE is an important DNA damage 
response pathway. 
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In Chitalia et al. (2008) the relationships between Jade1, β-catenin, and Wnt 
phases are brought into focus. Binding of Jade-1and β-catenin was found initially via 
coimmunoprecipitation showing their strong interactions and eventually leading to an 
understanding of their places in the Wnt signaling phases. This is important because β-
catenin functions as a transcriptional activator when transported into the nucleus (Nusse 
2005). Jade-1 presence in 786-O cells lowers the half-life of the cytosolic β-catenin, 
indicating it as a controlling factor (Chitalia et al. 2008). Dysregulation of β-catenin 
levels have been linked to a wide range of cancers (review by Howe & Brown, 2004). 
Due to the dynamic control of β-catenin by both Wnt activation and Jade-1 control there 
are multiple steps which can become damaged resulting in failure to regulate β-catenin 
properly.  
Unsurprisingly, mutations leading to constitutively active Wnt signaling pathway 
lead to other diseases such as Familial Adenomatous Polyposis by increasing 
concentrations of β-catenin in the nucleus (Nusse 2005).  The relationship between VHL 
stabilizing Jade-1, to β-catenin and Wnt, allows for tumor suppression and a dynamic 
management of transcription with multiple checkpoints and mediators. 
 
One mechanism of the Jade family comes from the short isoform Jade1s the 
alternatively spliced version of Jade-1 that lacks 333 C-terminal amino acids (Havasi et 
al. 2013). The presence of Jade-1S allows for a delay during cytokinesis while the 
absence of it increases the rate of faulty chromatin splitting resulting in multi-nuclear 
cells. This was further shown by upregulating Jade-1S concentration causing a larger 
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portion of cells captured during cytokinesis indicating the delay caused by raised levels 
(Siriwardana, Meyer, and Panchenko 2015).  Furthermore, Jade-1S is identifiable around 
the midbody during cytokinesis but focused at centrosomes during interphase. This is in 
comparison to other isoforms of Jade-1, which do not appear around the centrosomes or 
midbodies. Jade-1S undergoes phosphorylation during mitosis at the end of the G2 phase 
via a mitotic kinase causing it to dissociate from chromatin (reviewed in Panchenko, 
2016). The phosphorylation and dissociation of Jade-1S plays a role in the regulation of 
cytokinesis. This evidence shows Jade-1S as a unique regulating factor of cytokinesis 
(Siriwardana, Meyer, and Panchenko 2015). 
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Figure 1:  The relationship between Elongin proteins, Cul-2, pVHL, and HIF 
ubiquitination. Shown here is the function of normal pVHL interacting with Elongins C 
and B Cul-2 forming the pVHL/E3 ubiquitin ligase complex. 
 
Reprinted from Nyhan, M. J., O’Sullivan, G. C., & McKenna, S. L. (2008). Role of the 
VHL (von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor. 
Biochemical Society Transactions, 36(3), 472–478. https://doi.org/10.1042/BST0360472 
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METHODS  
 
Cell lines and treatment 
  Parental cells and stably transfected pools of 786-O clear-cell renal cell 
carcinomas were tested. Variants included parental (p), VHL transfected (VHL), and an 
empty vector (vector) controls. Cell lines were kept in RPMI with 10% fetal bovine 
serum and penicillin/streptomycin (100 μg/mL streptomycin). Cells were kept in a tissue 
culture incubator at 37 C and 5% CO2 concentration. Frozen stocks were made in 7% 
DMSO RPMI before being frozen down in a two-step process starting at -80 C before 
moving to liquid nitrogen cell storage (-196 C).  
Cells were prepared in 1mL RPMI across 6-well plates and left to grow to 70% 
confluence before treatment. Each treatment well with 1mL of media was given 300 ng 
neocarzinostatin as a DNA damaging agent with wells being exposed for 2, 4, 8, 16, or 24 
hours.  
At the end of the treatment period the 6-well plates were moved onto ice. Then 
500 µL NP 40 lysis buffer (250 mM NaCl, 50mM NaF, 1mM Na3VO4, 1mM 
phenylmethylsulfonyl fluoride (PMSF), 1% NP40 and a mixture of protease inhibitors 
was prepared. Wells were aspirated and washed with PBS. Each well was given 75 µL of 
the lysis buffer before being scraped with a cell scraper. The collected whole cell lysates 
were then subjected to a vortexing every 2 minutes repeated 5 times and were otherwise 
kept on ice. 
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 After the full 10 minutes of lysis, the lysates were centrifuged at 14,000 rpm for 
10 minutes in a cold room (4 C). The supernatant was moved into new centrifuge tubes 
while carefully avoiding disturbing the pellet of waste collected at the bottom. The 
collected protein extraction was kept at -80 C for preservation until later analysis. 
For protein quantification, each sample was tested in triplicate to ensure accurate 
evaluation. Two µLs of each lysate were added to centrifuge tubes containing 1 mL of 
Bio-Rad Protein Assay Dye Concentrate (Bradford assay). After inverting the vials to 
ensure proper mixing, 0.9mL was moved to cuvettes for use in a Beckman Coulter DU 
640 Spectrophotometry machine set to 795 nm. With the data gained from comparing a 
blank of the protein assay compared to the lysate mixtures, protein concentrations of each 
lysate could be estimated for extrapolation to loading values in gel electrophoresis 
 
Gel electrophoresis 
 The lysate proteins were subjected to size separation by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. The 7.5% polyacrylamide gels were submerged in 
Tris-Glycine-SDS Running Buffer from Boston Bioproducts. The gels were loaded with 
the protein lysates, markers, and a positive control and run for 130 minutes at 100 volts to 
separate captured proteins sufficiently for performing western blots.  
As the running gel was nearing completion preparation for transfer began. Laying 
out a transfer cassette, a sponge was added to each side after being soaked in transfer 
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buffer prepared with 10% methanol. Transfer buffer was kept chilled at 4 C for use. 
Whatman paper was cut to fit the gels were then soaked in the transfer buffer. Each 
sponge received two Whatman filter papers before being rolled out with a small glass 
roller. A Biorad 0.2 µm pore-size nitrocellulose membrane cut to fit the gel was then 
soaked in the transfer buffer before being moved onto the Whatman filter papers. More 
transfer buffer poured onto the nitrocellulose membrane with some careful leveling 
ensured an absence of air trapped.  
After removing the gels from the electrophoresis device, they were cut of 
extraneous regions (higher than the 75 kD marker and unused sidelanes) using a gel 
cutter. The prepared gel was washed in transfer buffer before being put onto the 
nitrocellulose membrane and closing the cassette. The transfer system was then loaded 
with the cassette. Addition of a frozen insert ensured the maintenance of cooler 
temperatures. After adding transfer buffer until the cassette was submerged, the entire 
system was placed in ice to ensure temperature control. The transfer apparatus was run 
for 75 minutes at 100 volts. 
 
 
Western Blot  
 After removal from the transfer system, the nitrocellulose membrane was washed 
in Ponceau stain for visualization. The membranes were trimmed of excess area and 
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marked using the stained protein size ladder, especially at the 50kD region, for guidance. 
Three 10-minute phosphate buffered saline with tween 20 (PBST) washes were followed 
by blocking for an hour long wash in 5% dry milk PBST. The membranes were then split 
at the 50kD marker to separate the Jade-1S region (appearing at 64kD) from β-actin 
region at 42 kD.  Monoclonal anti- β-actin antibody was from mouse while Jade-1S 
antibody was from rabbit. (1:5,000 concentration n 1% milk PBST) 
 Following an 8-hour incubation with the primary antibodies in a cold room (4 C) 
on a shaker, three 10-minute PBST washes were performed. Secondary antibodies for 
both mouse and rabbit were used respectively with an hour long incubation at room 
temperature on a rocker. Another three PBST washes were completed in preparation for 
development. 
 
 
 
Protein Detection and Analysis 
Thermo Scientific enhanced chemiluminescence (ECL) solution was used with 
incubation times of five minutes for the Jade-1S section of the blot and one minute for the 
β-actin region. The membranes were then brought to a dark room for developing with 
autoradiography film. Using varying time points ranging from five minutes to fractions of 
a second the films were exposed to the membrane and developed. The wide variety of 
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time points ensured the clearest data for usage in analysis. Occasionally the Jade-1S 
indicators would not appear with ECL solution. In these scenarios another set of 3 PBST 
washes was done before development using the much more sensitive Thermo Femto-ECL 
in place of normal ECL 
The films were then scanned before being converted into a gray-scale image for 
densitometry analysis (see Fig 2). Using the program ImageJ, the levels of Jade-1S and β-
actin were measured based on the exposure level of the autoradiography film. With the 
raw data, the Jade-1S levels at different time points were compared using β-actin as a 
loading control. 
The average expression of Jade-1S for each cell line was created using a 
minimum N=3 for each cell line. The base levels of Jade-1S for each line were collected 
from untreated wells for comparison and evaluation of the Jade-1S response to NCS 
exposure. Each of the cell lines were then compared using ANOVA tests while keeping 
the exposure durations constant. Using a one-way Analysis of variance (ANOVA) test, 
the three cell lines (parental, VHL, and vector) were compared for the variance of Jade-
1S levels for each of the different time points. 
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Figure 2: Developed film showing Jade-1S protein in 786-O VHL cells treated with 
NCS. NCS treatment time points included untreated, 2, 4, 8, 16, or 24 hours displayed on 
a Western blot. The black line drawn into the marker lane halfway down indicates the 
area for the Jade-1S band. The positive lane is used to identify the correct band for Jade-
1S. Jade-1S appears between 50 and 75 kD, while the β-actin is below the 50 kD. This 
film was exposed to the ECL covered membrane for one second resulting in a light 
image, from which it is easier to measure accurately 
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Figure 2: Developed film showing Jade-1S protein in 786-O VHL cells treated with 
NCS. NCS treatment time points included untreated, 2, 4, 8, 16, or 24 hours displayed on 
a Western blot. The black line drawn into the marker lane halfway down indicates the 
area for the Jade-1S band. The positive lane is used to identify the correct band for Jade-
1S. Jade-1S appears between 50 and 75 kD, while the β-actin is below the 50 kD. This 
film was exposed to the ECL covered membrane for one second resulting in a light 
image, from which it is easier to measure accurately. 
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RESULTS 
 
 Jade-1S is similarly induced in renal cells in culture, including human embryonic 
kidney 293T cells and the immortalized proximal tubule cell line HK-2, in response to 
DNA damage. In preliminary experiments, Delia found that Jade-1S is not inducible in 
parental 786-O renal cancer cells, which lack wild-type pVHL.  These experiments raised 
the question whether Jade-1 induction might be abnormal in renal cancer cells or whether 
Jade-1 induction might be dependent on pVHL.   
Since pVHL stabilizes Jade-1 protein, testing for dependence of Jade-1S 
induction on pVHL can be tested with the 786-O cell line. Significance of this 
information can be used confirm how pVHL deficient renal cells react to DNA damage.  
One hypothesis is that the pVHL deficient parental and vector lines will fail to show 
significant induction of Jade-1S unlike the VHL transfected cells or the other cells 
expressing wild-type cells, like 293T, HK-2 or MCF7 cells. 
Using different durations of exposure to NCS, the 786-O cell lines were tested for 
significant changes in Jade-1S protein levels. Initially, the VHL line was tested for pVHL 
expression by Western blotting to ensure its authenticity. Importantly, in a set of 3 
experiments with the parental, vector and VHL 786-O cell lines, I was unable to find a 
statistically significant induction of Jade-1S in response to NCS treatment at multiple time 
points over a 24-hour period (Figure 3).  This observation suggests that induction of Jade-
1 in response to NCS does not depend on the presence of pVHL.  Unfortunately, however, 
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using the known 293T cells as a positive control, I conducted the same experiment but was 
unable to elicit the expected Jade-1S induction with NCS as the DNA damaging agent. It 
is unclear why the positive control did not work.  With a failure to succeed with a positive 
control the negative result of Jade-1S induction in the renal cancer cells is less meaningful, 
and the validity of any conclusion of my experiment is undermined.  
The figures below show the Jade-1S responses from each cell line. Figure 3 has all 
of the data shown together, where Figures 4, 5, and 6 are broken down to show individual 
cell lines.  
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Figure 3: 786-O Jade-1S levels in response to NCS Treatment. All of the Jade-1S levels 
were compared to the levels measured in an untreated control.  Notably VHL-pool had 
the lowest variability and most predictable reaction to NCS treatment, displaying slightly 
increased Jade-1S levels in the shorter durations of NCS exposure and less pronounced 
during the 8 and 16 hour responses, ending with reduced levels at the 24-hour treatment. 
Vector and parental showed some of the most pronounced reactions at the 24-hour time 
point, with vector Jade-1S levels dropping to .77 compared to untreated. Parental showed 
an increased reaction but with much higher variability at most time points. 
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Figure 4: The reaction of Jade-1S levels in 786-Op. Shown above is the average response 
of 786-Op to different durations of NCS treatment. The cell line displayed a continuous 
increase in response to the DNA damaging agent with the highest average response at the 
24-hour duration. The high variance is attributed to the low number of repetitions. N=3 
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Figure 5: Mean Jade-1S levels in the 786-O empty vector cell line. Showing the 
repeatedly lowered Jade-1S levels after the 2-hour treatment. The high variation in error 
estimation comes from the number of repetitions of the experiment. N=3 
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Figure 6: Jade1s response in the 786-O VHL transfected line. Mostly raised levels of 
Jade-1S were found in the treatment of the stably transfected VHL line of 786-O. The 8-
hour treatment was only slightly above normal (1.004) however when accounting for 
variability could be raised or lowered from untreated levels. Additionally, the 24-hour 
time point had consistently lowered level as indicated by the lower mean and low 
variation. N=3 
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DISCUSSION 
 
 It would be expected that parental 786-O cells, which don’t produce pVHL, 
should have significantly lower Jade-1S response levels when compared to the VHL line. 
This is because of the stabilization of Jade-1S that pVHL provides, preventing its 
breakdown by proteasomes (Zhou PNAS 2005). This expectation would extend to the 
empty vector cell line as well. The results were inconclusive due to the failure of the 
positive control to work. There was also a higher than expected level of variability in 
Jade-1S protein expression as detected by immunoblotting in all the cell lines I used.  
This is most likely due to errors in reliably executing the protocol and handling at 
different steps. 
Hypothetically, the stably transfected VHL line of 786-O might be able to 
maintain a significantly higher concentration of Jade-1S as demonstrated in Zhou PNAS 
2005. The stabilization by pVHL prevents Jade-1 degradation by the proteasome 
breakdown pathway which normally limits the measurable response to DNA damage 
(Zhou PNAS 2005). It is worth noting that although pVHL is required to stabilize Jade-
1S for sustained higher levels, a positive response of Jade-1S is still expected in VHL 
deficient cells when compared to untreated, but to a reduced extent. Consequently, a 
smaller increase in 786-O Jade-1S levels in parental and vector lines might be expected in 
response to DNA damage in contrast to the stronger induction that might be expected in 
786-O VHL cells. 
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Examining lncRNA-JADE is another potential way to assess the induction of 
Jade-1S in the 786-O cell line, or any of the others. Some control of transcriptional 
induction of Jade1S is mediated through lncRNA-JADE, which is upregulated in 
response to DNA damage (Wan et al 2013). Inspecting how lncRNA-JADE levels relate 
in terms of different VHL deficient cells lines and cancerous cell lines work holds 
promise for potential research. 
 The wide array of effects and pathways mediated by VHL should continue to be 
investigated due to their nature in tumorigenesis. They provide a promising link to cancer 
treatment. Possible areas for further research could include measuring the branching 
patterns of 786-O cells under increasingly DNA damage. This could provide insight into 
how the invasiveness of VHL deficient tumors varies with more stress put on the DNA 
damage repair pathway, similar to the research done earlier by Koochekpour et al. (1999).  
Another potential avenue for investigation lies in the management of HIF for 
VHL negative patients. The downregulation of HIF2 α through short hairpin RNAs is 
shown to adequately mitigate tumor formation in pVHL negative renal cell carcinomas 
(Kondo et al. 2003).  
Yet another method of managing VHL patients lies in the concept of synthetic 
lethality. Synthetic lethality occurs when a singular functioning gene allows for viable 
cell life but failure of both leads to cell death (Kaelin Jr 2005). This provides for a 
promising approach to diseases like VHL. VHL patients are heterozygous with one faulty 
VHL gene. The threat to VHL patients comes with the random chance of cells receiving 
DNA damage resulting in inactivation of the single functioning VHL gene. Some 
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promising therapeutic potential arises because of this, specifically aiming at pVHL 
deficient cells without harming healthy cells in the process. For example, Turcotte et al. 
(2008) found STF-62247, a small molecule that shows specificity for VHL deficient cells 
and functions as a cytotoxin by promoting apoptosis. As we develop more specific 
treatments and show their safety, we may be able to provide an equivalent medical 
effectiveness to current day cancer treatment while limiting the collateral damage caused 
by more general treatments. 
The isoforms of Jade-1 have been shown to have drastically different effects. 
Effects on the extracellular matrix effects and communication mediated by another Jade1 
isoform indicate another mechanism of control. In a study of Jade-1 response to renal 
ischemia Jade-1S initially dropped in levels, but increased as cell proliferation ramped 
up. The recovery of Jade1Long (J1L) levels occurs only after most proliferation has 
completed (Havasi et al. 2013). This might indicate it as a marker for slowing replication 
after recovering from trauma. 
The difference in Jade isoforms and the nuanced effects of each could provide 
insight into kidney proliferation and recovery from injuries. Other potential topics of 
interest include looking further into VHL’s control on cell differentiation in other regions 
as compared to Wnt. The potential for learning how to grow and maintain organs outside 
of the body could lie further down the path of understanding tissue differentiation. This 
will almost certainly be required for more complex organ treatment in severe damage. 
In conclusion, the relationships between lncRNA-JADE, Jade-1, and VHL are key 
to understanding renal tumor suppression. Continuing research into the induction of 
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lncRNA-JADE and its control of the Jade-1 protein is a relatively new and very 
promising avenue for the future of renal tumor therapeutics.  
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